Literature DB >> 32841430

Novel thiazole-pyrazolone hybrids as potent ACE inhibitors and their cardioprotective effect on isoproterenol-induced myocardial infarction.

Hongwen You1, Xinyou Su2, Guoying Su3.   

Abstract

A facile synthesis of a group of novel thiazole-pyrazolone hybrids and their investigation for angiotensin-converting enzyme (ACE) inhibition are reported in this study. These compounds were synthesized using a well-known approach, based on the condensation of ethyl acetoacetate with thiazolylhydrazines, and characterized by various spectroscopic and analytical techniques. The entire set of compounds displayed a moderate-to-excellent inhibitory activity against ACE. In particular, compound 4i was found to be the most potent ACE inhibitor and was further studied for cardioprotective effects against isoproterenol (ISO)-induced myocardial infarction (MI) in rats. Compound 4i improved the cardiac function and prevented cardiac injury induced by ISO in Sprague Dawley rats. The levels of oxidative stress and proinflammatory cytokines were also restored to near normal by 4i as compared with the ISO group. In the Western blot analysis, compound 4i prevented mitochondrial apoptosis after MI by downregulating the expression of cleaved caspase-3 and Bax, with the upregulation of Bcl-2, as compared with the ISO group.
© 2020 Deutsche Pharmazeutische Gesellschaft.

Entities:  

Keywords:  ACE; inflammation; myocardial infarction; oxidative stress; thiazole

Mesh:

Substances:

Year:  2020        PMID: 32841430     DOI: 10.1002/ardp.202000140

Source DB:  PubMed          Journal:  Arch Pharm (Weinheim)        ISSN: 0365-6233            Impact factor:   3.751


  1 in total

1.  Pyrazolone-type compounds: synthesis and in silico assessment of antiviral potential against key viral proteins of SARS-CoV-2.

Authors:  Jovica Branković; Vesna M Milovanović; Dušica Simijonović; Slađana Novaković; Zorica D Petrović; Snežana S Trifunović; Goran A Bogdanović; Vladimir P Petrović
Journal:  RSC Adv       Date:  2022-05-27       Impact factor: 4.036

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.